Cubist announced that it has submitted a New Drug Application (NDA) to the FDA for its investigational antibiotic, ceftolozane/tazobactam for the treatment of Complicated Urinary Tract Infections (cUTI) and Complicated Intra-Abdominal Infections (cIAI). Ceftolozane is a cephalosporin antibiotic; tazobactam is a β-lactamase inhibitor.
The NDA submission is based on positive data from pivotal Phase 3 clinical trials in cUTI and cIAI. The primary endpoints were met in the Phase 3 studies. Results of the secondary analyses were consistent with and supportive of the primary outcomes.
Previously in 2013, the FDA granted ceftolozane/tazobactam Fast Track status for its Qualified Infectious Disease Product (QIDP) indications of cUTI and cIAI, as well as Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP). Cubist is currently in the process of initiating investigational sites for a pivotal Phase 3 clinical trial of ceftolozane/tazobactam in HABP/ VABP.
For more information call (866) 793-2786 or visit Cubist.com.